Teachers Advisors LLC Increases Holdings in Dynavax Technologies Corporation (NASDAQ:DVAX)

Teachers Advisors LLC grew its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 8.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,805 shares of the biopharmaceutical company’s stock after acquiring an additional 6,855 shares during the period. Teachers Advisors LLC owned 0.18% of Dynavax Technologies Corporation worth $867,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Dynavax Technologies Corporation by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 1,700 shares during the period. Bank of America Corp DE lifted its position in Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares in the last quarter. Legal & General Group Plc lifted its position in Dynavax Technologies Corporation by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares in the last quarter. CAPROCK Group Inc. bought a new stake in Dynavax Technologies Corporation during the 2nd quarter worth about $134,000. Finally, American International Group Inc. lifted its position in Dynavax Technologies Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,584 shares in the last quarter. Hedge funds and other institutional investors own 58.55% of the company’s stock.

A number of brokerages have recently issued reports on DVAX. Cowen and Company reaffirmed a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies Corporation in a report on Friday, November 3rd. Cantor Fitzgerald started coverage on shares of Dynavax Technologies Corporation in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 price target on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $28.00 price target (up from $26.00) on shares of Dynavax Technologies Corporation in a report on Monday, September 25th. ValuEngine upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, William Blair reiterated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Dynavax Technologies Corporation has an average rating of “Buy” and an average target price of $25.17.

WARNING: “Teachers Advisors LLC Increases Holdings in Dynavax Technologies Corporation (NASDAQ:DVAX)” was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/14/dynavax-technologies-corporation-dvax-shares-bought-by-teachers-advisors-llc.html.

Dynavax Technologies Corporation (NASDAQ:DVAX) opened at $18.35 on Tuesday. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business’s quarterly revenue was down 68.8% on a year-over-year basis. During the same period last year, the company posted ($0.90) earnings per share. analysts anticipate that Dynavax Technologies Corporation will post -1.72 earnings per share for the current year.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply